share_log

Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90

Moomoo 24/7 ·  Apr 22 12:44

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $82 to $90.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment